| BioHelix goes out on its own, joins Beverly cluster New England Biolabs spinoff BioHelix Corp. is leaving the nest and establishing its own headquarters after five years under its parent’s wing. feeds.bizjournals.com |
Maryland Reins In Hospital Costs Maryland's experience with setting hospital rates suggests the federal government could realize savings on health spending, but at a price of more regulation for health providers. online.wsj.com |
A N.I.C.E. Development for Generex Oral-lyn in the U.K. R.J Steffens submits:The United Kingdom's National Institute for Health and Clinical Excellence (NICE) has recently begun the draft scope for the official Health Technology Appraisal of Generex's (GNBT) novel buccal insulin for the management of type 1 diabetes. Oral-lyn is not yet licensed for sale in the UK. Oral-lyn is in Phase III trials for patients with Type 1 diabetes and Generex is consequently moving closer towards submission to the Medicines and Healthcare products Regulatory Agency MHRA. At present, over 350 patients have been enrolled in the Phase III program at 70 clinical sites around the world.NICE produces guidance on public health, health technologies and clinical practice for England, Wales, Northern Ireland and Scotland. These are recommendations, based on the best available evidence, on the appropriate treatment and care of people with specific diseases and conditions. NICE does not license drugs or devices. Licensing drugs and devices in the UK is done by MHRA. A recommendation by NICE ends any uncertainty and inequality about prescribing. Once national guidance has been issued by NICE, it replaces local recommendations.Complete Story » seekingalpha.com |
Synta Pharmaceuticals Corp. Q3 2009 Earnings Call Transcript Synta Pharmaceuticals Corp. (SNTA)Q3 2009 Earnings CallNovember 4, 2009 10:00 am ETComplete Story » seekingalpha.com |
Waters Looks Undervalued Value Expectations submits: The Applied Finance Group’s (AFG’s) valuation techniques help investors identify and take advantage of mispriced securities in the market. One way investors can identify over or undervalued stocks is by using AFG’s Intrinsic Value Chart, which displays a company’s intrinsic value relative to its trading range and helps entry/exit points. This easy to read chart identifies how far a stock’s trading range deviates from its intrinsic value (target price assuming immediate decay), which helps you recognize potentially mispriced stocks and pursue long and short opportunities. AFG’s Intrinsic Value Chart also contains a company’s Value Score (ranked valuation attractiveness), Economic Margin Change (expected improvement of economic profitability), and Accuracy (how well AFG’s default valuation has tracked the company) information. AFG’s valuation framework estimates a company’s equity value by subtracting debt and other liabilities from the total enterprise value. The total enterprise value is estimated by discounting projected future cash flows, utilizing analyst consensus, Economic Margin methodology, and the Decay concept which addresses the perpetuity bias in the traditional DCF model.Complete Story » seekingalpha.com |